Clinical Trial Kits Market Share, Size, Trends, Industry Analysis Report, By Service (Kitting Solutions {Drug Kits, Sample Collection kits}, and Logistics {transportation, warehousing & storage, others}), By Phase (Phase I, Phase II, Phase III and Phase I

Clinical Trial Kits Market Share, Size, Trends, Industry Analysis Report, By Service (Kitting Solutions {Drug Kits, Sample Collection kits}, and Logistics {transportation, warehousing & storage, others}), By Phase (Phase I, Phase II, Phase III and Phase IV), By Region; Segment Forecast, 2022 - 2030

The global clinical trial kits market is anticipated to grow up to USD 2.85 billion by 2030 according to a new study by Polaris Market Research. The report “Clinical Trial Kits Market Share, Size, Trends, Industry Analysis Report, By Service (Kitting Solutions {Drug Kits, Sample Collection kits}, and Logistics {transportation, warehousing & storage, others}), By Phase (Phase I, Phase II, Phase III and Phase IV), By Region; Segment Forecast, 2022–2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The major factors driving the global market include the globalization of clinical trials and rising clinical trial complexity. Remote medical trial services are becoming an essential part of patient satisfaction, safety, and retention. At present, pharmaceutical companies are partnering with global logistics partners in order to provide direct-to-patient services.

The logistics segment is leading the global industry in 2021. This huge market share can be attributed to the growing demand for services in order to simplify the overall logistics process in medical tests. Additionally, pharmaceutical companies are partnering up with global logistics companies in order to provide remote services. This is anticipated to drive the growth of the segment over the coming years.

Based on Phase, the phase III segment is anticipated to dominate the industry in 2021. The basic objective of Phase III is to validate the safety and efficacy of a new medicine or vaccine, confirm the dosage levels, and discover the side effects. The number of clinical tests on humans increases in Phase III. Most of the medicines that passed phase II clinical trials generally fail in Phase III due to the side effects of therapeutic effectiveness.